• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Earnings And Buybacks Just Shift United Therapeutics (UTHR) Investment Narrative?

    Simply Wall St·11/13/2026 01:18:13
    Listen to the news
    • United Therapeutics reported third quarter 2026 sales of US$832.5 million versus US$799.5 million a year earlier, while net income and diluted EPS from continuing operations declined compared with the prior period.
    • The drug maker also completed a sizeable share repurchase program, buying back 3,523,789 shares for about US$2.0b, which materially reduced its share count.
    • Next, the focus shifts to how United Therapeutics' investment narrative is shaped by EPS pressure alongside this completed US$2.0b buyback.

    Spot opportunities that echo the EPS pressure and capital returns story at United Therapeutics by scanning our curated list of 20 high quality undiscovered gems with similar fundamentals under the radar.

    What Is United Therapeutics' Investment Narrative?

    Owning United Therapeutics is really a bet on disciplined execution in complex, high-need diseases. The latest quarter shows that sales were close to flat year to date while earnings per share from continuing operations moved lower, so near term, this is less a top line growth story and more about how efficiently the portfolio is run. For a shareholder, the belief has to be that management can keep demand and pricing for pulmonary arterial hypertension therapies resilient enough to support ongoing research in organ platforms without letting capital intensity erode returns.

    The recently completed US$2.0b buyback, which retired 8.13% of the share base, sits right inside that narrative. Shrinking the float can soften the optical impact of EPS pressure, although the latest quarter shows that operational headwinds can still dominate the earnings line. That makes upcoming data readouts, regulatory milestones and competitive responses around Tyvaso and treprostinil franchises the key near term swing factors, while the organ and xenotransplantation pipeline stays more of a long game.

    Yet beneath the EPS story and the confident capital return, there is a more awkward dependency that hinges on ...

    There's only one way to know the right time to buy, sell or hold United Therapeutics. Head to Simply Wall St's company report for the latest analysis of United Therapeutics's Fair Value.

    NasdaqGS:UTHR 1-Year Stock Price Chart
    NasdaqGS:UTHR 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on United Therapeutics leans hard into competition risk. The lowest analysts were already assuming revenue of about US$3.1b and earnings of roughly US$1.3b by 2029, with earnings per share near US$26.22. Those forecasts came before this EPS update, so you should expect some opinions to shift and explore how yours compares.

    Explore 3 other United Therapeutics fair value estimates, including one that suggests it could be worth just $687.14.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    • A great starting point for your United Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • See our latest analysis for United Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate United Therapeutics' overall financial health at a glance.

    Looking For More Investment Ideas Beyond United Therapeutics?

    If the United Therapeutics story has you thinking about risk, reward and capital allocation, it can help to scan a broader set of companies that fit the kind of profile you want in your portfolio.